Loading…
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $67M | $-468M | $-438M | $-397M | -57.2% | 4.4% | -16.1% |
| 2024 | $64M | $-538M | $-522M | $-454M | -45.4% | 61.3% | -15.1% |
| 2023 | $39M | $-651M | $-615M | $-800M | -38.7% | -97.5% | -219.2% |
| 2022 | $1.6B | $840M | $516M | $1.6B | 24.8% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,580.47 | 39.49 | 63.71 | 66.52 |
| Operating Revenue | - | 1,580.47 | 37.38 | 61.37 | 63.13 |
| Cost Of Revenue | - | 146.32 | 2.76 | 0.84 | 0.03 |
| Gross Profit | - | 1,434.15 | 36.73 | 62.87 | 66.49 |
| Operating Expense | - | 601.08 | 707.48 | 615.04 | 546 |
| Research And Development | - | 474.65 | 579.72 | 506.50 | 455.97 |
| Selling General And Administration | - | 161.76 | 174.44 | 119.03 | 92.07 |
| Total Expenses | - | 747.40 | 710.24 | 615.88 | 546.03 |
| Operating Income | - | 833.07 | -670.75 | -552.17 | -479.51 |
| Total Operating Income As Reported | - | 833.07 | -684.30 | -587.16 | -479.33 |
| EBITDA | - | 839.85 | -651.29 | -537.61 | -467.83 |
| Normalized EBITDA | - | 950.99 | -615.85 | -497.09 | -469.74 |
| EBIT | - | 833.07 | -670.75 | -552.17 | -479.51 |
| Interest Income | - | 28.09 | 86.99 | 71.81 | 40.24 |
| Net Interest Income | - | 28.09 | 86.99 | 71.81 | 40.24 |
| Other Non Operating Income Expenses | - | 4.26 | -8.99 | -2.22 | -0.41 |
| Other Income Expense | - | -106.88 | -44.44 | -42.74 | 1.50 |
| Interest Income Non Operating | - | 28.09 | 86.99 | 71.81 | 40.24 |
| Net Non Operating Interest Income Expense | - | 28.09 | 86.99 | 71.81 | 40.24 |
| Pretax Income | - | 754.28 | -628.19 | -523.10 | -437.77 |
| Tax Provision | - | 238.44 | -13.08 | -1.14 | 0.22 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -35.12 | -0.74 | -0.08 | 0.40 |
| Net Income Continuous Operations | - | 515.84 | -615.12 | -521.96 | -437.99 |
| Net Income From Continuing And Discontinued Operation | - | 515.84 | -615.06 | -521.96 | -437.99 |
| Net Income From Continuing Operation Net Minority Interest | - | 515.84 | -615.06 | -521.96 | -437.99 |
| Net Income | - | 515.84 | -615.06 | -521.96 | -437.99 |
| Net Income Common Stockholders | - | 515.84 | -615.06 | -521.96 | -437.99 |
| Net Income Including Noncontrolling Interests | - | 515.84 | -615.12 | -521.96 | -437.99 |
| Normalized Income | - | 591.86 | -580.36 | -481.52 | -439.50 |
| Diluted NI Availto Com Stockholders | - | 515.84 | -615.06 | -521.96 | -437.99 |
| Basic Average Shares | - | 132.61 | 134.13 | 136.25 | 138.52 |
| Diluted Average Shares | - | 134.81 | 134.13 | 136.25 | 138.52 |
| Reconciled Depreciation | - | 6.78 | 19.45 | 14.56 | 11.68 |
| Reconciled Cost Of Revenue | - | 146.32 | 2.76 | 0.84 | 0.03 |
| Total Unusual Items | - | -111.14 | -35.45 | -40.52 | 1.91 |
| Total Unusual Items Excluding Goodwill | - | -111.14 | -35.45 | -40.52 | 1.91 |
| Minority Interests | - | 0 | 0.06 | 0 | 0 |
| Special Income Charges | - | 0 | -13.56 | -34.99 | 0.18 |
| Restructuring And Mergern Acquisition | - | 0 | 13.56 | 34.99 | -0.18 |
| Gain On Sale Of Security | - | -111.14 | -21.89 | -5.53 | 1.73 |
| Other Operating Expenses | - | -35.33 | -46.69 | -10.49 | -2.04 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc.this co. | VIR | $1.5B | - | 2.02 | -57.2% | - |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| 2.93 |
| -49.1% |
| - |
| Sonida Senior Living, Inc. | SNDA | $1.6B | -22.19 | -142770.48 | 643445.5% | 96.78 |
| ArriVent BioPharma, Inc. | AVBP | $1.5B | - | 5.02 | -54.1% | - |
| PROCEPT BioRobotics Corporation | PRCT | $1.5B | -16.08 | 4.20 | -26.1% | -15.56 |
| AnaptysBio, Inc. | ANAB | $1.5B | - | 40.41 | -35.6% | 17.42 |
| Peer Median | - | -13.54 | 5.11 | -48.3% | -7.18 | |